Evidence map›Paper›PMID 30455705›Full record

ArticleFrontiers in immunology2018

Encephalitis Associated to Metabotropic Glutamate Receptor 5 (mGluR5) Antibodies in Cerebrospinal Fluid.

Carlos Guevara, Gonzalo Farias, Carlos Silva-Rosas, Pablo Alarcon, Gabriel Abudinen, Julio Espinoza, Andrés Caro, Heather Angus-Leppan, Jose de Grazia

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Clinical features and brain MRI volumetric changes in anti-mGluR5 encephalitis.Annals of clinical and translational neurology · 2023
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Carlos GuevaraFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Gonzalo FariasFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Carlos Silva-RosasFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Pablo AlarconFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Gabriel AbudinenFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Julio EspinozaFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Andrés CaroFaculty of Medicine, Universidad de Chile, Santiago, Chile.
Heather Angus-LeppanClinical Neurosciences, Royal Free London NHS Foundation Trust, London, United Kingdom.
Jose de GraziaFaculty of Medicine, Universidad de Chile, Santiago, Chile.
University of Chile · CLUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 68-years-old Hispanic man, complained of night sweats, low grade fewer, unexplained weight loss, and memory problems over 3 months. Abdominal tomography showed multiple intra-abdominal adenopathy and biopsy confirmed classic Hodgkin's lymphoma. He commenced treatment with chemotherapy. Three months later, he had acute onset of inattention, auditory hallucinations and alterations of anterograde memory. The patient developed psychomotor agitation, unresponsive to a combination of neuroleptics and benzodiazepines. Brain MRI showed a small established cerebellar infarction. Electroencephalogram was normal. Tests for toxic metabolic encephalopathy were negative. One oligoclonal IgG bands was found in the Cerebrospinal fluid (CSF), which was not observed in corresponding serum, but cell count and protein were normal. Extensive testing for infectious encephalitis was unremarkable. CSF testing for commercially available neural and non-neural autoantibodies was negative. The patient fulfilled the Gultekin diagnostic criteria for paraneoplastic limbic encephalitis and methylprednisolone IV 1g/d for 5 days was given. He recovered rapidly, with progressive improvement in memory and psychomotor agitation. After treatment commenced, results for antibodies to mGluR5 in CSF taken prior to treatment were returned as positive. mGluR5 is found on post-synaptic terminals of neurons and microglia and is expressed primarily in the hippocampus and amygdala. This case highlights the difficulties in diagnosing this type of encephalitis: the CSF did not show pleocytosis, the MRI showed only chronic change and the electroencephalogram was normal. The dramatic recovery after methylprednisolone help to better characterized the clinical spectrum of auto-immune encephalitis. Diagnosing anti mGlutR5 encephalitis may lead to potentially highly effective treatment option and may anticipate the diagnostic of a cancer. A high index of suspicion is needed to avoid missed diagnosis. In patients with unexplained encephalitis, testing for antibodies to mGluR5 in CSF and serum should be considered. When there is a reasonable index of suspicion of auto-immune encephalitis, treatment should not be delayed for the antibody results.

Indexed as

AgedAutoantibodiesEncephalitisHashimoto DiseaseHodgkin DiseaseHumansImmunoglobulin GLimbic EncephalitisMaleMethylprednisoloneReceptor, Metabotropic Glutamate 5AutoantibodiesGRM5 protein, humanImmunoglobulin GMethylprednisoloneReceptor, Metabotropic Glutamate 5encephalitisHodgkin's lymphomalimbic encephalitismetabotropic glutamate receptor 5Ophelia syndrome

Identifiers

PMID30455705
PMCPMC6230718
OpenAlexW2899840633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.